The final presentation, a poster entitled Brilacidin, Host Defense Peptide Mimetic, One of a New Class of Immunomodulatory Agents that can Target Multiple Disease Indications, will be given in the category of New Antimicrobials. “This is an important poster, as it highlights the immunomodulatory properties of Brilacidin, in addition to its antimicrobial properties,” Dr. Jorgensen added. “These animal data support the use of topical Brilacidin in humans to prevent or ameliorate oral mucositis, a painful condition in cancer patients undergoing chemoradiation therapy. A phase 2 clinical trial is about to begin.” - See more at: http://cellceutix.com/cellceutix-phase-2b-clinical-trial-of-brilacidin-accepted-for-oral-presentation-at-the-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid/#sthash.gYBYcCYv.dpuf
Here's the other poster TOB. We should be able to view abstracts on Wednesday. Possibly news before then?
Title Brilacidin, host defence peptide mimetic, one of a new class of immunomodulatory agents that can target multiple disease indications
Poster No: EV0201 Author(s): Scott Richard W., Sonis Stephen T., Kroczak Bozena, Freeman Katie B., DeGrado William F, Holden Sylvia A., Kumar Ashok, Chafai-Fadela Karima, Ram Siya, Menon Krishna Affiliation(s): Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, NewMed, Wayne PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, University of California, San Francisco CA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA, Fox Chase Chemical Diversity Center, Doylestown PA, USA Session: EV06 Antimicrobials: new antimicrobials Date: Saturday - April 25, 2015 00:00 Location: ePoster Area Subtopic: Antimicrobials: new antimicrobials Topic: ePoster Viewing